Research Reports

Anglo French Drugs & Industries Unlisted Shares

Anglo French Drugs & Industries company logo

Anglo French Drugs & Industries Share Price

PHYSICAL

PUBLIC LIMITED

Price Chart

1W
1M
1Y
MAX

High

₹3,168

Low

₹605

Return

201.61%

Anglo French Drugs & Industries Essentials

As of April 24, 2026, Anglo French Drug & Industries, Unlisted Shares are trading at ₹2,428.00 per share and face value is ₹10.00/share, with a 52-week high of ₹2,750.00 and 52-week low of ₹2,428.00. The minimun lot size is 120 shares, and the shares are traded on NSDL and CDSL.

ISIN

info icon

INE570E01016

Face Value

info icon

10

Total Shares

info icon

12,91,000

Market Cap

info icon

313.45 Cr

Profit After Tax

info icon

-12.34 Cr

Total Revenue

info icon

95.2 Cr

P/E

info icon

-25.4

P/B

info icon

2.76

Sector

info icon

Health Care

Sub-sector

info icon

Pharmaceuticals

Category

info icon

Listed on Small Exchange

Cashflow - Operations

info icon

-0.06 Cr

About Anglo French Drugs & Industries

  • Anglo French Drugs & Industries Ltd. ("AFDIL" or "The company"), is primarily involved in the manufacturing of pharmaceutical formulation, which primarily involves mixing various chemical compounds into active drugs/ingredients. The company is the formulator, supplier, and distributor of drugs and medicines across nutraceuticals, CNS, skin, and respiratory segments. 
  • From being an importer of medicines in 1923, the company has emerged as the manufacturer, marketer, and distributor of over 350 products across the world; over a period of 100 years.
  • AFDIL currently has the following divisions: AFD Pharma, Hospicare, Optima, Trading, and Export. AFD Pharma focuses on products for wellness and immunity, for the aging population; Hospicare products are focused on orthopedic doctors and general health; Optima division ensures the optimal supply of AFD's medicines; Trading division ensures the supply of raw materials to pharma. manufacturers; Export division focuses on AFDIL's export operations.
  • The company's product portfolio involves the manufacturing of vitamins, anti-epileptics, anti-oxidants, sleep-inducing agents, cold and cough preparations, protein food supplements, digestive enzymes, and calcium supplements. 
  • AFDIL is India's first pharmaceutical company to manufacture single vitamin injections and a combination of B-complex Vitamins.
  • AFDIL has announced the release of a new product called AFD-NP for the treatment of neuropathic pain, which has received approval from the Drug Control Department. The company has also ventured into 2 new categories: Respiratory Care, and Fertility space; by launching products in these segments.
  • AFDIL initiated its exports in 1997 and currently has its presence in 16 countries across Eastern Europe, South East Asia, and Africa.
  • During the year 2021-2022, the Company sold a portfolio of their brands to Lupin Ltd for a lump-sum consideration of approximately 305 crores. The consideration received will be utilized in different ways: development of new markets; development of new products; marketing in new countries; marketing to more and different institutions; new avenues of business such as rural sales and digital marketing; and investment
  • The company was incorporated in 1923 and has its registered office in Bengaluru, Karnataka.
  • The company is listed on Metropolitan Stock Exchange of India (MSEI), but it has not been traded on MSEI for the last 3 financial years. The last traded price is Rs 145.50

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Anglo French Drugs & Industries Media

News

Articles

Videos

Anglo-French Drugs & Industries reports standalone net loss of Rs 0.44 crore in the March 2025 quarter

Anglo-French Drugs & Industries reports standalone net loss of Rs 0.44 crore in the March 2025 quarter

02 May 2025

Business Standard

Anglo-French Drugs & Industries reports standalone net profit of Rs 3.10 crore in the March 2024 quarter

Anglo-French Drugs & Industries reports standalone net profit of Rs 3.10 crore in the March 2024 quarter

30 May 2024

Business Standard

Anglo-French Drugs & Industries reports standalone net loss of Rs 3.35 crore in the December 2023 quarter

Anglo-French Drugs & Industries reports standalone net loss of Rs 3.35 crore in the December 2023 quarter

14 Feb 2024

Business Standard

Frequently Asked Question (FAQs)

Where can I find the annual report of Anglo French Drug & Industries Ltd?

The annual report of Anglo French Drug & Industries Ltd is available in the annual report section.

How to buy Anglo French Drug & Industries Unlisted Shares?

Please find below the procedure for buying Anglo French Drug & Industries Unlisted Shares at Planify.
• 1. You confirm booking of Anglo French Drug & Industries Unlisted Shares with us at a trading price.
• 2. You provide your client master report (ask the broker if not available) along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
• 3. We will provide the bank details.
• 4. You need to transfer funds in that account.
• 5. Payment has to be done in RTGS/NEFT/IMPS CHEQUE TRANSFER. No CASH DEPOSIT.
• 6. Payment has to be done from the same account in which shares are to be credited.
• 7. We will transfer the shares in 24 hours if funds are credited before 2 pm.
Important Note: Please note that the lock-in period for selling Anglo French Drug & Industries Unlisted Shares is 6 months after listing. Hence you can’t sell Anglo French Drug & Industries Unlisted Shares which you bought in Pre-IPO for 6 months after its listing. i.e. You can sell it only after 6 months calculated from the listing date.

What is the lock-in period of Anglo French Drug & Industries Unlisted Shares?

Lock-in period of Anglo French Drug & Industries Unlisted Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of Anglo French Drug & Industries Unlisted Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of Anglo French Drug & Industries Unlisted Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.

See More

Anglo French Drugs & Industries

₹ 2,428

cartIcon